Oncobiologics (ONS) Receives Consensus Rating of “Hold” from Analysts

Shares of Oncobiologics (NASDAQ:ONS) have earned an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.

Zacks has also given Oncobiologics an industry rank of 146 out of 255 based on the ratings given to related companies.

Separately, ValuEngine raised Oncobiologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of ONS stock traded down $0.01 during trading hours on Friday, hitting $0.83. The stock had a trading volume of 117,331 shares, compared to its average volume of 139,349. Oncobiologics has a one year low of $0.78 and a one year high of $2.30. The company has a quick ratio of 0.22, a current ratio of 0.22 and a debt-to-equity ratio of -0.10.

About Oncobiologics

Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply